{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:58:39Z","timestamp":1762430319302},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.3816\/clm.2007.n.005","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:56Z","timestamp":1221095456000},"page":"291-295","source":"Crossref","is-referenced-by-count":41,"title":["Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular Lymphoma"],"prefix":"10.3816","volume":"7","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariapaola","family":"Fina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Farsad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2007.n.005_bib1","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.n.005_bib2","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","article-title":"Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma","volume":"22","author":"Zinzani","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMoa042040","article-title":"Groupe d'Etude des Lymphomes de l'Adulte (GELA). ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma","volume":"352","author":"Reyes","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.n.005_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as Initials treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.3816\/CLM.2007.n.005_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00259-003-1165-6","article-title":"PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma","volume":"30","author":"Schiepers","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3816\/CLM.2007.n.005_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00259-003-1375-y","article-title":"FDG-PET\/CT in re-staging of patients with lymphoma","volume":"31","author":"Freudenberg","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3816\/CLM.2007.n.005_bib7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1023\/A:1008327127033","article-title":"The role of positron emission tomography (PET) in the management of lymphoma patients","volume":"10","author":"Zinzani","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/sj.bjc.6602040","article-title":"Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients","volume":"91","author":"Zinzani","year":"2004","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2007.n.005_bib9","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.bjc.6601561","article-title":"Substantial impact of FDG PET imaging on the therapy decision in patients with earlystage Hodgkin's lymphoma","volume":"90","author":"Naumann","year":"2004","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2007.n.005_bib10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4","article-title":"Whole body positron emission tomography in the treatment of Hodgkin's disease","volume":"91","author":"Hueltenschmidt","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.n.005_bib11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1365-2141.2001.03169.x","article-title":"Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?","volume":"115","author":"Spaepen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.n.005_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdg011","article-title":"Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease","volume":"14","author":"Jerusalem","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib13","first-page":"4464","article-title":"Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose","volume":"91","author":"Romer","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.005_bib14","first-page":"1018","article-title":"PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease","volume":"43","author":"Kostakoglu","year":"2002","journal-title":"J Nucl Med"},{"key":"10.3816\/CLM.2007.n.005_bib15","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"13","author":"Spaepen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.005_bib17","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.005_bib18","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Schoder","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib19","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","article-title":"Utility of FDG-PET scanning in lymphoma by WHO classification","volume":"101","author":"Elstrom","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.005_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CLM.2003.n.013","article-title":"Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma","volume":"4","author":"Blum","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLM.2007.n.005_bib21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1023\/A:1011169332265","article-title":"Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)","volume":"12","author":"Jerusalem","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000070290","article-title":"18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma","volume":"64","author":"Hoffmann","year":"2003","journal-title":"Oncology"},{"key":"10.3816\/CLM.2007.n.005_bib23","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.n.005_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","article-title":"Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma","volume":"14","author":"McLaughlin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib27","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/10428190009113384","article-title":"18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma \u2013 comparison with CT","volume":"39","author":"Mikhaeel","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2007.n.005_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.3816\/CLM.2007.n.005_bib30","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLM.2007.n.005_bib31","first-page":"1211","article-title":"Uptake of carbon-11methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study","volume":"32","author":"Leskinen-Kallio","year":"1991","journal-title":"J Nucl Med"},{"key":"10.3816\/CLM.2007.n.005_bib32","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1023\/A:1008312726163","article-title":"Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type","volume":"10","author":"Hoffmann","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.n.005_bib33","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:09:58Z","timestamp":1588918198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011700634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S1557919011700634"],"URL":"https:\/\/doi.org\/10.3816\/clm.2007.n.005","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}